Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference GlobeNewswire - Mon Dec 2, 3:05PM CST

VTVT : 14.96 (+3.03%)
VTv Therapeutics: Q3 Earnings Snapshot AP - Tue Nov 12, 4:04PM CST

VTv Therapeutics: Q3 Earnings Snapshot

VTVT : 14.96 (+3.03%)
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire - Tue Nov 12, 3:05PM CST

VTVT : 14.96 (+3.03%)
VTv Therapeutics: Q2 Earnings Snapshot AP - Thu Aug 8, 4:26PM CDT

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 14.96 (+3.03%)
VTv Therapeutics: Q1 Earnings Snapshot AP - Thu May 9, 4:02PM CDT

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 14.96 (+3.03%)
VTv Therapeutics: Q4 Earnings Snapshot AP - Wed Mar 13, 7:24AM CDT

VTv Therapeutics: Q4 Earnings Snapshot

VTVT : 14.96 (+3.03%)
VTv Therapeutics: Q3 Earnings Snapshot AP - Thu Nov 9, 2023

VTv Therapeutics: Q3 Earnings Snapshot

VTVT : 14.96 (+3.03%)
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 14.96 (+3.03%)
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer PR Newswire - Tue Sep 26, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 14.96 (+3.03%)
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 14.96 (+3.03%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025 Barchart - Sun Dec 22, 4:00PM CST
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot